Results from two phase III trials presented at the EULAR 2018 meeting in Amsterdam, the Netherlands, suggest that treatment with the Janus kinase inhibitor upadacitinib alone or in combination with conventional DMARDs may be beneficial for patients with rheumatoid arthritis.
In this piece, Sarah Patterson and Patricia Katz discuss the benefits of exercise, and the barriers to increasing physical activity, in patients with systemic lupus erythematosus.
The addition of abatacept to standard therapy does not increase the rate of complete renal response among patients with lupus nephritis, phase III study findings show.
Patients with juvenile idiopathic arthritis who are treated with etanercept do not have a higher risk for developing uveitis than those given methotrexate, results of a UK cohort study suggest.
Belimumab, a B-lymphocyte stimulator specific inhibitor used for the treatment of systemic lupus erythematosus, has a stable safety profile over 8 years of follow-up, with no new safety signals observed, report researchers.
Researchers have found molecular changes appearing in the synovial tissue that precede rheumatoid arthritis development and may tell us more about the pathogenesis of the disease and treatment targets.
